Imalumab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | BAX69 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Imalumab (BAX69) is an experimental monoclonal antibody against macrophage inhibitory factor (MIF), a cytokine known to exacerbate tumor growth.[1][2][3] and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer.[2] It was developed by Cytokine PharmaSciences and Baxalta, which was purchased by Shire Pharmaceuticals.[4]
A phase I/II trial in patients with malignant ascites was terminated in 2016.[4]
